STOCK TITAN

[8-K] Scholastic Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Luther King Capital Management Corp. (LKCM) and its founder, J. Luther King, Jr., have filed Amendment No. 6 to Schedule 13G for scPharmaceuticals Inc. (SCPH) dated 30 Jun 2025. The filing discloses continued beneficial ownership above the 5 % threshold:

  • LKCM reports 3,541,170 common shares with sole voting and dispositive power, representing 6.7 % of SCPH’s outstanding stock.
  • J. Luther King, Jr. individually reports 3,669,170 common shares (sole voting/dispositive power) for a 7.0 % stake.

The amendment confirms that the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. Both reporting persons classify as an “Investment Adviser” (LKCM) and “Individual” (King) under Rule 13d-1(b). No joint filing or group status is claimed, and there are no shared voting or dispositive powers.

Implications for investors: 1) LKCM remains one of SCPH’s larger institutional holders, potentially signaling confidence in the company’s prospects. 2) Because the ownership level is stable at ~7 %, the amendment itself does not suggest an imminent change in strategic direction or control. 3) Any future movement above or below the 5 % threshold would trigger additional filings, providing transparency on LKCM’s trading activity.

Luther King Capital Management Corp. (LKCM) e il suo fondatore, J. Luther King, Jr., hanno presentato l'Emendamento n. 6 al Modulo 13G per scPharmaceuticals Inc. (SCPH) datato 30 giugno 2025. La comunicazione rivela una detenzione continuativa di azioni superiore alla soglia del 5%:

  • LKCM dichiara di possedere 3.541.170 azioni ordinarie con potere esclusivo di voto e disposizione, rappresentando il 6,7% del capitale sociale di SCPH.
  • J. Luther King, Jr. dichiara individualmente 3.669.170 azioni ordinarie (con potere esclusivo di voto e disposizione), pari a una quota del 7,0%.

L'emendamento conferma che le azioni sono detenute nell'ordinaria attività aziendale e non con l'intento di influenzare il controllo dell'emittente. Entrambi i soggetti segnalanti sono classificati rispettivamente come “Consulente per gli Investimenti” (LKCM) e “Individuo” (King) ai sensi della Regola 13d-1(b). Non viene rivendicata alcuna presentazione congiunta o status di gruppo, né vi sono poteri condivisi di voto o disposizione.

Implicazioni per gli investitori: 1) LKCM rimane uno dei principali azionisti istituzionali di SCPH, segnalando potenzialmente fiducia nelle prospettive della società. 2) Poiché il livello di partecipazione è stabile intorno al 7%, l'emendamento non suggerisce un cambiamento imminente nella direzione strategica o nel controllo. 3) Qualsiasi futura variazione al di sopra o al di sotto della soglia del 5% comporterebbe ulteriori comunicazioni, garantendo trasparenza sulle attività di trading di LKCM.

Luther King Capital Management Corp. (LKCM) y su fundador, J. Luther King, Jr., han presentado la Enmienda No. 6 al Schedule 13G para scPharmaceuticals Inc. (SCPH) con fecha 30 de junio de 2025. La presentación revela una propiedad beneficiaria continua por encima del umbral del 5 %:

  • LKCM reporta 3,541,170 acciones comunes con poder exclusivo de voto y disposición, representando el 6.7 % del capital social en circulación de SCPH.
  • J. Luther King, Jr. reporta individualmente 3,669,170 acciones comunes (con poder exclusivo de voto y disposición) para una participación del 7.0 %.

La enmienda confirma que las acciones se mantienen en el curso ordinario del negocio y no con el propósito de influir en el control del emisor. Ambas personas informantes se clasifican como “Asesor de Inversiones” (LKCM) y “Individuo” (King) bajo la Regla 13d-1(b). No se reclama presentación conjunta ni estatus de grupo, y no existen poderes compartidos de voto o disposición.

Implicaciones para los inversores: 1) LKCM sigue siendo uno de los mayores accionistas institucionales de SCPH, lo que podría indicar confianza en las perspectivas de la empresa. 2) Dado que el nivel de propiedad se mantiene estable alrededor del 7 %, la enmienda en sí no sugiere un cambio inminente en la dirección estratégica o el control. 3) Cualquier movimiento futuro por encima o por debajo del umbral del 5 % desencadenaría presentaciones adicionales, proporcionando transparencia sobre la actividad comercial de LKCM.

Luther King Capital Management Corp.(LKCM)와 창립자 J. Luther King, Jr.는 2025년 6월 30일자 scPharmaceuticals Inc.(SCPH)에 대한 Schedule 13G 수정서 6호를 제출했습니다. 이 제출서는 5% 기준을 초과하는 지속적인 실질 소유권을 공개합니다:

  • LKCM는 단독 의결권 및 처분권을 가진 3,541,170주 보통주를 보유하고 있으며, 이는 SCPH 발행 주식의 6.7%에 해당합니다.
  • J. Luther King, Jr.는 개인적으로 단독 의결 및 처분권을 가진 3,669,170주 보통주를 보유하여 7.0%의 지분을 보고했습니다.

수정서는 해당 주식이 발행자의 통제에 영향을 미치기 위한 목적이 아닌 정상적인 사업 과정에서 보유되고 있음을 확인합니다. 두 보고자는 각각 규칙 13d-1(b) 하에 “투자 자문가”(LKCM)“개인”(King)으로 분류됩니다. 공동 제출이나 그룹 지위는 주장하지 않으며, 의결권이나 처분권도 공유하지 않습니다.

투자자에 대한 시사점: 1) LKCM은 SCPH의 주요 기관 투자자 중 하나로 남아 있어 회사의 전망에 대한 신뢰를 나타낼 수 있습니다. 2) 소유 지분이 약 7%로 안정적이므로 이번 수정서는 전략적 방향이나 통제의 즉각적인 변화를 시사하지 않습니다. 3) 앞으로 5% 기준선을 넘거나 밑돌 경우 추가 제출이 요구되어 LKCM의 거래 활동에 대한 투명성이 확보됩니다.

Luther King Capital Management Corp. (LKCM) et son fondateur, J. Luther King, Jr., ont déposé l’Amendement n° 6 au Schedule 13G pour scPharmaceuticals Inc. (SCPH) daté du 30 juin 2025. Le dépôt révèle une détention bénéficiaire continue au-dessus du seuil de 5 % :

  • LKCM déclare 3 541 170 actions ordinaires avec pouvoir exclusif de vote et de disposition, représentant 6,7 % du capital en circulation de SCPH.
  • J. Luther King, Jr. déclare individuellement 3 669 170 actions ordinaires (pouvoir exclusif de vote/disposition) pour une participation de 7,0 %.

L’amendement confirme que les actions sont détenues dans le cours normal des affaires et non dans le but d’influencer le contrôle de l’émetteur. Les deux déclarants sont classés respectivement comme « Conseiller en investissement » (LKCM) et « Individu » (King) selon la Règle 13d-1(b). Aucun dépôt conjoint ou statut de groupe n’est revendiqué, et aucun pouvoir de vote ou de disposition partagé n’existe.

Implications pour les investisseurs : 1) LKCM reste l’un des plus grands détenteurs institutionnels de SCPH, ce qui peut refléter une confiance dans les perspectives de la société. 2) Étant donné que le niveau de détention est stable autour de 7 %, l’amendement lui-même ne suggère pas de changement imminent de direction stratégique ou de contrôle. 3) Tout mouvement futur au-dessus ou en dessous du seuil de 5 % déclencherait des dépôts supplémentaires, assurant ainsi la transparence des activités de trading de LKCM.

Luther King Capital Management Corp. (LKCM) und dessen Gründer J. Luther King, Jr. haben am 30. Juni 2025 die Änderung Nr. 6 zum Schedule 13G für scPharmaceuticals Inc. (SCPH) eingereicht. Die Meldung offenbart weiterhin einen wirtschaftlichen Eigentum über der 5 %-Schwelle:

  • LKCM berichtet über 3.541.170 Stammaktien mit alleinigem Stimm- und Verfügungsrecht, was 6,7 % des ausstehenden Aktienkapitals von SCPH entspricht.
  • J. Luther King, Jr. meldet individuell 3.669.170 Stammaktien (alleiniges Stimm-/Verfügungsrecht) mit einem Anteil von 7,0 %.

Die Änderung bestätigt, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit der Absicht, die Kontrolle über den Emittenten zu beeinflussen. Beide Meldenden werden gemäß Regel 13d-1(b) als „Investmentberater“ (LKCM) bzw. „Einzelperson“ (King) klassifiziert. Es wird kein gemeinsames Melden oder Gruppenstatus beansprucht, und es bestehen keine geteilten Stimm- oder Verfügungsrechte.

Folgen für Investoren: 1) LKCM bleibt einer der größeren institutionellen Anteilseigner von SCPH, was auf Vertrauen in die Aussichten des Unternehmens hindeuten könnte. 2) Da der Besitzstand stabil bei etwa 7 % liegt, deutet die Änderung selbst nicht auf eine unmittelbar bevorstehende Änderung der strategischen Ausrichtung oder Kontrolle hin. 3) Jede zukünftige Bewegung oberhalb oder unterhalb der 5 %-Schwelle würde weitere Meldungen auslösen und so Transparenz über die Handelsaktivitäten von LKCM schaffen.

Positive
  • Significant passive stake maintained: LKCM and its founder still control roughly 7 % of SCPH, indicating continued institutional confidence.
Negative
  • Potential overhang risk: A 7 % holder could create selling pressure if LKCM decides to exit, though no such intent is stated.

Insights

TL;DR: LKCM re-affirms ≈7 % SCPH stake; neutral impact, signals ongoing institutional support without control intent.

LKCM’s 3.5 M-share position (6.7 %) and King’s 3.7 M (7.0 %) confirm a meaningful, yet passive, ownership block. The absence of shared voting rights and the certification of non-control intent suggest LKCM remains a traditional, long-only holder rather than an activist. For existing shareholders, this provides a modest vote of confidence and liquidity support but does not alter SCPH’s strategic trajectory. The filing is routine—an amendment required as positions or share counts change modestly—so market impact should be limited.

Luther King Capital Management Corp. (LKCM) e il suo fondatore, J. Luther King, Jr., hanno presentato l'Emendamento n. 6 al Modulo 13G per scPharmaceuticals Inc. (SCPH) datato 30 giugno 2025. La comunicazione rivela una detenzione continuativa di azioni superiore alla soglia del 5%:

  • LKCM dichiara di possedere 3.541.170 azioni ordinarie con potere esclusivo di voto e disposizione, rappresentando il 6,7% del capitale sociale di SCPH.
  • J. Luther King, Jr. dichiara individualmente 3.669.170 azioni ordinarie (con potere esclusivo di voto e disposizione), pari a una quota del 7,0%.

L'emendamento conferma che le azioni sono detenute nell'ordinaria attività aziendale e non con l'intento di influenzare il controllo dell'emittente. Entrambi i soggetti segnalanti sono classificati rispettivamente come “Consulente per gli Investimenti” (LKCM) e “Individuo” (King) ai sensi della Regola 13d-1(b). Non viene rivendicata alcuna presentazione congiunta o status di gruppo, né vi sono poteri condivisi di voto o disposizione.

Implicazioni per gli investitori: 1) LKCM rimane uno dei principali azionisti istituzionali di SCPH, segnalando potenzialmente fiducia nelle prospettive della società. 2) Poiché il livello di partecipazione è stabile intorno al 7%, l'emendamento non suggerisce un cambiamento imminente nella direzione strategica o nel controllo. 3) Qualsiasi futura variazione al di sopra o al di sotto della soglia del 5% comporterebbe ulteriori comunicazioni, garantendo trasparenza sulle attività di trading di LKCM.

Luther King Capital Management Corp. (LKCM) y su fundador, J. Luther King, Jr., han presentado la Enmienda No. 6 al Schedule 13G para scPharmaceuticals Inc. (SCPH) con fecha 30 de junio de 2025. La presentación revela una propiedad beneficiaria continua por encima del umbral del 5 %:

  • LKCM reporta 3,541,170 acciones comunes con poder exclusivo de voto y disposición, representando el 6.7 % del capital social en circulación de SCPH.
  • J. Luther King, Jr. reporta individualmente 3,669,170 acciones comunes (con poder exclusivo de voto y disposición) para una participación del 7.0 %.

La enmienda confirma que las acciones se mantienen en el curso ordinario del negocio y no con el propósito de influir en el control del emisor. Ambas personas informantes se clasifican como “Asesor de Inversiones” (LKCM) y “Individuo” (King) bajo la Regla 13d-1(b). No se reclama presentación conjunta ni estatus de grupo, y no existen poderes compartidos de voto o disposición.

Implicaciones para los inversores: 1) LKCM sigue siendo uno de los mayores accionistas institucionales de SCPH, lo que podría indicar confianza en las perspectivas de la empresa. 2) Dado que el nivel de propiedad se mantiene estable alrededor del 7 %, la enmienda en sí no sugiere un cambio inminente en la dirección estratégica o el control. 3) Cualquier movimiento futuro por encima o por debajo del umbral del 5 % desencadenaría presentaciones adicionales, proporcionando transparencia sobre la actividad comercial de LKCM.

Luther King Capital Management Corp.(LKCM)와 창립자 J. Luther King, Jr.는 2025년 6월 30일자 scPharmaceuticals Inc.(SCPH)에 대한 Schedule 13G 수정서 6호를 제출했습니다. 이 제출서는 5% 기준을 초과하는 지속적인 실질 소유권을 공개합니다:

  • LKCM는 단독 의결권 및 처분권을 가진 3,541,170주 보통주를 보유하고 있으며, 이는 SCPH 발행 주식의 6.7%에 해당합니다.
  • J. Luther King, Jr.는 개인적으로 단독 의결 및 처분권을 가진 3,669,170주 보통주를 보유하여 7.0%의 지분을 보고했습니다.

수정서는 해당 주식이 발행자의 통제에 영향을 미치기 위한 목적이 아닌 정상적인 사업 과정에서 보유되고 있음을 확인합니다. 두 보고자는 각각 규칙 13d-1(b) 하에 “투자 자문가”(LKCM)“개인”(King)으로 분류됩니다. 공동 제출이나 그룹 지위는 주장하지 않으며, 의결권이나 처분권도 공유하지 않습니다.

투자자에 대한 시사점: 1) LKCM은 SCPH의 주요 기관 투자자 중 하나로 남아 있어 회사의 전망에 대한 신뢰를 나타낼 수 있습니다. 2) 소유 지분이 약 7%로 안정적이므로 이번 수정서는 전략적 방향이나 통제의 즉각적인 변화를 시사하지 않습니다. 3) 앞으로 5% 기준선을 넘거나 밑돌 경우 추가 제출이 요구되어 LKCM의 거래 활동에 대한 투명성이 확보됩니다.

Luther King Capital Management Corp. (LKCM) et son fondateur, J. Luther King, Jr., ont déposé l’Amendement n° 6 au Schedule 13G pour scPharmaceuticals Inc. (SCPH) daté du 30 juin 2025. Le dépôt révèle une détention bénéficiaire continue au-dessus du seuil de 5 % :

  • LKCM déclare 3 541 170 actions ordinaires avec pouvoir exclusif de vote et de disposition, représentant 6,7 % du capital en circulation de SCPH.
  • J. Luther King, Jr. déclare individuellement 3 669 170 actions ordinaires (pouvoir exclusif de vote/disposition) pour une participation de 7,0 %.

L’amendement confirme que les actions sont détenues dans le cours normal des affaires et non dans le but d’influencer le contrôle de l’émetteur. Les deux déclarants sont classés respectivement comme « Conseiller en investissement » (LKCM) et « Individu » (King) selon la Règle 13d-1(b). Aucun dépôt conjoint ou statut de groupe n’est revendiqué, et aucun pouvoir de vote ou de disposition partagé n’existe.

Implications pour les investisseurs : 1) LKCM reste l’un des plus grands détenteurs institutionnels de SCPH, ce qui peut refléter une confiance dans les perspectives de la société. 2) Étant donné que le niveau de détention est stable autour de 7 %, l’amendement lui-même ne suggère pas de changement imminent de direction stratégique ou de contrôle. 3) Tout mouvement futur au-dessus ou en dessous du seuil de 5 % déclencherait des dépôts supplémentaires, assurant ainsi la transparence des activités de trading de LKCM.

Luther King Capital Management Corp. (LKCM) und dessen Gründer J. Luther King, Jr. haben am 30. Juni 2025 die Änderung Nr. 6 zum Schedule 13G für scPharmaceuticals Inc. (SCPH) eingereicht. Die Meldung offenbart weiterhin einen wirtschaftlichen Eigentum über der 5 %-Schwelle:

  • LKCM berichtet über 3.541.170 Stammaktien mit alleinigem Stimm- und Verfügungsrecht, was 6,7 % des ausstehenden Aktienkapitals von SCPH entspricht.
  • J. Luther King, Jr. meldet individuell 3.669.170 Stammaktien (alleiniges Stimm-/Verfügungsrecht) mit einem Anteil von 7,0 %.

Die Änderung bestätigt, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit der Absicht, die Kontrolle über den Emittenten zu beeinflussen. Beide Meldenden werden gemäß Regel 13d-1(b) als „Investmentberater“ (LKCM) bzw. „Einzelperson“ (King) klassifiziert. Es wird kein gemeinsames Melden oder Gruppenstatus beansprucht, und es bestehen keine geteilten Stimm- oder Verfügungsrechte.

Folgen für Investoren: 1) LKCM bleibt einer der größeren institutionellen Anteilseigner von SCPH, was auf Vertrauen in die Aussichten des Unternehmens hindeuten könnte. 2) Da der Besitzstand stabil bei etwa 7 % liegt, deutet die Änderung selbst nicht auf eine unmittelbar bevorstehende Änderung der strategischen Ausrichtung oder Kontrolle hin. 3) Jede zukünftige Bewegung oberhalb oder unterhalb der 5 %-Schwelle würde weitere Meldungen auslösen und so Transparenz über die Handelsaktivitäten von LKCM schaffen.

false000086672900008667292025-07-162025-07-16

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 16, 2025

 

 

SCHOLASTIC CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-19860

13-3385513

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

557 Broadway

 

New York, New York

 

10012

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 343-6100

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

SCHL

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

 


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b) On July 16, 2025, John L. Davies and David P. Young tendered their resignations as directors to the Board of Directors of the Company (the "Board"), which were accepted. Mr. Davies had been a director elected by the holders of the Company’s Common Stock (“Common Shares”) and Mr. Young a director elected by the holders of the Company’s Class A Stock (“Class A Shares”). In addition, also on July 16, 2025, Alix Guerrier, a director who had been elected by the holders of Common Shares, tendered his resignation to the Board, as a director which was accepted. However, as noted below, Mr. Guerrier was then elected to the Board to replace Mr. Young.

(d) On July 16, 2025, the directors elected by the holders of the Company’s Class A Shares ("Class A Directors"), in accordance with the Company’s by-laws, elected Mr. Alix Guerrier as a Class A Director to fill the vacancy arising from Mr. Young’s resignation. On this same date, the directors elected by the holders of the Company’s Common Shares (“Common Directors”) elected Ms. Anne Clark Wolff and Ms. Milena Alberti as Common Directors to fill the vacancies arising from the resignations of John L. Davies and Alix Guerrier as Common Directors.

Alix Guerrier

Mr. Guerrier, 48 years old, who was first elected to the Board in March 2024, currently serves as the Chief Executive Officer for DonorsChoose, a leading nonprofit organization that supports public schools in the United States through the use of its crowdfunding platform. As CEO, Mr. Guerrier works to ensure DonorsChoose maintains a focus on equity while expanding its broad appeal and advancing its mission to serve students in every community. Prior to DonorsChoose, Mr. Guerrier served for three years as the CEO of GlobalGiving, a nonprofit organization and global crowdfunding community that enables donors to support charitable projects around the world. In 2011, Mr. Guerrier co-founded LearnZillion, an educational technology company offering school districts a free, cloud-based curriculum, which was subsequently acquired by Edgenuity and Weld North Education. Prior to that, Mr. Guerrier had a five-and-a-half-year career with McKinsey & Company, first as an Associate in the company's Healthcare Practice and then as an Engagement Manager and Expert in McKinsey's Education Practice. Mr. Guerrier began his career in education by serving as a teacher for the Pan American School of Porto Alegre in Brazil and then as a sixth-grade math and science teacher at Costaño Elementary School in East Palo Alto, California, as part of Teach for America. He then spent two years as a math teacher for Leadership High School in San Francisco, California. Mr. Guerrier has an AB degree in Physics from Harvard University, a Master's degree in Education from Stanford University, and an MBA from Stanford University.

Anne Clark Wolff

Ms. Wolff, 60 years old, is the Founder and Chief Executive Officer of Independence Point Advisors, an independent investment bank and advisory services firm formed in 2021. Previously, Ms. Wolff was a Managing Director at Bank of America from 2011 until 2020, during which time she served as Chairman, Global Corporate and Investment Banking and Head of Global Corporate Banking and Leasing. Prior to that, from 2009 to 2011, Ms. Wolff held senior positions at JP Morgan Chase & Company and from 1998 to 2009 at Citigroup. Ms. Wolff began her career at Salomon Brothers, where she held positions of increasing responsibility from 1989 to 1998. Ms. Wolff serves (since 2018) as an independent director of Amphenol Corp., a New York Stock Exchange listed company, that is a leading global provider of interconnect, sensor, and antenna solutions.

Ms. Wolff earned a BA degree from Colby College, where she was also previously Vice Chairman of the Board of Trustees. She has an MBA from Northwestern University—Kellogg School of Management.

Milena Alberti

Ms. Alberti, age 51, is the non-executive Chair (since 2024) and independent director (since 2023) of Pitney Bowes Inc., a New York Stock Exchange traded company that provides software as a service platforms to manage shipping logistics, advanced mailing systems and services and financial services. She is the former Chief Financial Officer of Getty Images, Inc., the world’s leading visual content company, from January 2021 to January 2022. Prior to that, Ms. Alberti served as the Chief Financial Officer of MediaMath, a demand-side platform for programmatic marketing and

 


 

advertising, from January 2020 to December 2020. Ms. Alberti worked in a variety of financial and publishing roles from 2001 to 2017 at Penguin Random House, the world’s largest book publisher, and was the global and U.S. CFO from 2015 until 2017. As a member of management, she served as a non-voting member of its Board of Directors and its audit committee. Ms. Alberti also worked in financial analyst and research roles at Lehman Brothers and Morgan Stanley. Ms. Alberti has extensive experience on for-profit and not-for-profit Boards, including currently serving on the Boards of National Public Radio and Jumpstart. Ms. Alberti is an independent director (since 2024) of Allurion Technologies, Inc., a New York Stock Exchange traded healthcare company focused on combating obesity through a non-surgical weight loss platform, and she was formerly an independent director (2022-2024) of Digimarc Corporation, a technology company specializing in digital watermarking and product digitization.

Independence

The Board has determined that each of Mr. Guerrier, Ms. Wolff and Ms. Alberti are independent for the purposes of the rules of the Nasdaq Stock Market (NASDAQ listing standards) and for the purposes of SEC Rule 10A-3.

Director Compensation

As outside (non-employee) directors, Mr. Guerrier, Ms. Wolff, and Ms. Alberti will each be entitled to receive an annual cash retainer (currently set at $95,000) for their services. In addition, the Scholastic Corporation 2017 Outside Directors Stock Incentive Plan (the “2017 Plan”) provides for annual equity awards to the outside directors on the date of each annual meeting of stockholders. For fiscal 2025, restricted stock units (“RSUs”) were awarded to each outside director having a value of $125,000. Mr. Guerrier has received the entire award for fiscal 2025 which was made in September 2024. In accordance with the terms of the 2017 Plan, on the date of their election to the Board, Ms. Wolff and Ms. Alberti were each awarded RSUs with a grant date value equal to $25,000 (20% of the full year equity award). On July 16, 2025, the Board confirmed that compensation for outside directors would remain unchanged for fiscal 2026 (i.e., annual cash retainer of $95,000 and an equity award in the form of RSUs with a grant date value of $125,000). Awards under the 2017 Plan are determined by the Board prior to the Company’s annual meeting of stockholders to become automatically effective on the date of the annual meeting for each of the outside directors elected at such meeting.

Pursuant to the terms of the 2017 Plan, the stock options and restricted stock units vest on the earlier of the first anniversary of the date of grant or the next annual meeting of stockholders following the date of grant. The 2017 Plan permits outside directors to elect a tax deferral option in respect to restricted stock unit awards under the 2017 Plan pursuant to which an outside director can elect to defer receipt of all or a portion of the shares of Common Stock underlying such awards in accordance with procedures established by the HRCC. Provided that the election is timely made in accordance with the applicable procedures, the deferral election remains in effect and continues to apply to restricted stock unit awards to the outside director for subsequent years until the outside director timely revokes or changes the deferral election.

Under the terms of the Scholastic Corporation Directors’ Deferred Compensation Plan, outside directors are permitted to defer 50% or 100% of their cash retainers and other fees. Deferred amounts accrue interest at a rate equal to the 30-year United States Treasury bill rate and are paid in cash upon the later of termination from Board service or the end of the deferral period, unless paid earlier due to death, disability, change-of-control of the Company or severe financial hardship.

Committees

Ms. Wolff and Ms. Alberti were each appointed as a member of the Board’s Audit Committee and Ms. Alberti was also appointed as a member of the Board’s Human Resources and Compensation Committee at the July 16, 2025 Board Meeting. In his capacity as a Class A Director, Mr. Guerrier was appointed as a member of the Board’s Nominating and Governance Committee and Technology, Data and Supply Chain Committee and will no longer serve as a member of the Board’s Human Resources and Compensation Committee.


Related Party Transactions

 


 

There have been no transactions nor are there any proposed transactions between the Registrant and any of (i) Mr. Guerrier, (ii) Ms. Wolff or (iii) Ms. Alberti that would require separate disclosure pursuant to Item 404(a) of Regulation S-K.

Reference is also made to the press release dated July 17, 2025, attached hereto as Exhibit 99.1, announcing the new Board appointments.

 

 


 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Number

Title of Exhibit

99.1

Press Release of the Registrant dated July 17, 2025 announcing new Board appointments.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SCHOLASTIC CORPORATION

 

 

 

 

Date:

July 21, 2025

By:

/s/ Chris Lick

 

 

Name:

Title:

Chris Lick
Executive Vice President, General Counsel and Secretary
 

 

 


FAQ

Why did LKCM file an Amendment 6 Schedule 13G for SCPH?

To update its passive ownership disclosure, confirming a 6.7 % stake as of 30 Jun 2025.

How many scPharmaceuticals shares does J. Luther King, Jr. own?

He reports 3,669,170 common shares, representing 7.0 % of SCPH.

Is LKCM seeking control of scPharmaceuticals?

No. The certification states the shares are held in the ordinary course and not to influence control.

What triggers future 13G/13D filings for SCPH?

Any ownership change that moves LKCM above or below key thresholds (5 %, or 1 % increments thereafter) requires an updated filing.

Does the filing indicate a change in SCPH’s strategy or governance?

The filing is passive; it does not signal any strategic or governance changes at SCPH.
Scholastic Corp

NASDAQ:SCHL

SCHL Rankings

SCHL Latest News

SCHL Latest SEC Filings

SCHL Stock Data

578.03M
21.43M
32.82%
86.09%
6.63%
Publishing
Books: Publishing Or Publishing & Printing
Link
United States
NEW YORK